SBP-9330, a new mGlu2-targeting medicine to help adults stop smoking
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers
This work will test whether SBP-9330 is safe, how the body processes it, and how it should be manufactured for adults who smoke.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11136953 on NIH RePORTER |
What this research studies
Researchers are preparing SBP-9330 for a Phase 2 trial in adult smokers. They will complete safety and toxicology studies, measure how the drug is absorbed, distributed, metabolized, and excreted (ADME), and finalize manufacturing and quality controls (CMC). The team will build on Phase 1 data in healthy volunteers and smokers plus animal studies to choose safe dose levels and monitoring plans. If you join a future trial you may have blood tests, side-effect monitoring, and regular clinic visits about smoking and cravings.
Who could benefit from this research
Good fit: Adult cigarette smokers aged 21 and older who are willing to participate in clinical research related to smoking cessation.
Not a fit: Non-smokers, people under 21, pregnant individuals, or those with disqualifying medical conditions are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, SBP-9330 could become a better-tolerated medication to help people quit smoking.
How similar studies have performed: In animal models, mGlu2 PAMs reduced nicotine self-administration, and a Phase 1 trial showed SBP-9330 was well tolerated in healthy volunteers and smokers.
Where this research is happening
La Jolla, United States
- Sanford Burnham Prebys Medical Discovery Institute — La Jolla, United States (Active)
Researchers
- Principal investigator: Cosford, Nicholas David — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Cosford, Nicholas David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.